Literature DB >> 31499137

Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model.

Marloes Duijm1, Noëlle C van der Voort van Zyp2, Paul van de Vaart2, Esther Oomen-de Hoop3, Mirjam E Mast3, Mischa S Hoogeman3, Joost J Nuyttens3.   

Abstract

PURPOSE: The treatment of central lung tumors with stereotactic body radiation therapy (SBRT) is challenged by the risk of excessive esophageal toxicity. To improve clinical decision making, we aimed to derive normal tissue complication probability (NTCP) models in a patient cohort with central lung tumors treated with SBRT and to evaluate the currently used esophagus dose constraints. METHODS AND MATERIALS: Patients with a central lung tumor who received SBRT (8 fractions of 7.5 Gy or 12 fractions of 5 Gy) were included. Doses were recalculated to an equivalent dose of 2 Gy with an α/β-ratio of 10 Gy for acute and 3 Gy for late toxicity (the cut-off was 3 months). The esophagus was manually delineated. NTCP modeling based on logistic regression was used to relate dose-volume histogram parameters (Dmax, D1cc, D2cc, D5cc) to acute and late toxicity. Parameters with a P < .05 were included in the model. Based on the NTCP models, we determined the probability of toxicity for the currently used dose constraints: D1cc ≤40 Gy for 8 fractions and D1cc ≤48 Gy for 12 fractions.
RESULTS: For this study, 188 patients with 203 tumors were eligible. Esophagus toxicity occurred in 33 patients (18%). Late high-grade toxicity consisted of 2 possible treatment-related deaths (grade 5) and 2 patients with grade 3 toxicity. Acute toxicity consisted of only grade 1 (n = 19) and grade 2 toxicity (n = 10). All investigated dose-volume histogram parameters were significantly correlated to acute and late toxicity. The probability of late high-grade toxicity is 1.1% for 8 fractions and 1.4% for 12 fractions when applying the current dose constraints.
CONCLUSIONS: High-grade esophageal toxicity occurred in 2.1% of the patients, including 2 possible treatment-related deaths. The currently used dose constraints correspond to a low risk of high-grade toxicity.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31499137     DOI: 10.1016/j.ijrobp.2019.08.059

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience.

Authors:  Elodie Guillaume; Ronan Tanguy; Myriam Ayadi; Line Claude; Sandrine Sotton; Coralie Moncharmont; Nicolas Magné; Isabelle Martel-Lafay
Journal:  Br J Radiol       Date:  2021-11-26       Impact factor: 3.039

2.  Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).

Authors:  Sebastian Regnery; Jonas Ristau; Fabian Weykamp; Philipp Hoegen; Simon David Sprengel; Katharina Maria Paul; Carolin Buchele; Sebastian Klüter; Carolin Rippke; Claudia Katharina Renkamp; Moritz Pohl; Jan Meis; Thomas Welzel; Sebastian Adeberg; Stefan Alexander Koerber; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Radiat Oncol       Date:  2022-05-25       Impact factor: 4.309

3.  Half-Brain Delineation for Prediction of Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.

Authors:  Qing-Hua Du; Yi-Xiu Gan; Ren-Sheng Wang; Wen-Qi Liu; Jian Li; Fei-Fei Liang; Xiang-De Li; Hui-Jun Zhu; Xue Ou; Qiu-Lu Zhong; Dan-Jing Luo; Zhi-Peng Zhu; Shang-Yong Zhu
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

4.  Oesophageal IGRT considerations for SBRT of LA-NSCLC: barium-enhanced CBCT and interfraction motion.

Authors:  Katrina Woodford; Vanessa Panettieri; Jeremy D Ruben; Sidney Davis; Trieumy Tran Le; Stephanie Miller; Sashendra Senthi
Journal:  Radiat Oncol       Date:  2021-11-14       Impact factor: 3.481

5.  Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer.

Authors:  Xiaojiang Sun; Yefei Li; Yaoyao Zhu; Qian Li; Xiaoshuai Yuan; Qingren Lin; Denghu Weng; Qinghua Xu; Hui Liu; Yaping Xu
Journal:  Transl Lung Cancer Res       Date:  2020-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.